BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
Authors:
Open Access
- 19 October 2010
- journal article
- Published by Public Library of Science (PLoS) in PLoS Currents
- Vol. 2, RRN1187
Abstract
Colon and rectal cancer (CRC) are the third most common cancer in the United States and cause approximately 50,000 deaths per year. The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (Erbitux®) and panitumumab (Vectibix®) have been recently introduced to treat CRC. However, the response rate with these agents is low and they are associated with serious adverse effects. Accordingly biomarkers that can predict those patients that will respond to treatment may have clinical utility. The p.Val600Glu sequence variant (often called V600E) in the BRAF gene has been investigated as a biomarker to predict patients that will not respond to treatment with the anti-EGFR monoclonal antibodies.Keywords
This publication has 29 references indexed in Scilit:
- BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcomeBritish Journal of Cancer, 2010
- Is BRAF Mutation Associated with Interval Colorectal Cancers?Digestive Diseases and Sciences, 2010
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 TrialJournal of Clinical Oncology, 2010
- KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS TrialJournal of Clinical Oncology, 2009
- Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosisInternational Journal of Cancer, 2009
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal CancerJNCI: Journal of the National Cancer Institute, 2009
- Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancerBritish Journal of Cancer, 2009
- EGFR Antagonists in Cancer TreatmentNew England Journal of Medicine, 2008
- Cetuximab for the Treatment of Colorectal CancerNew England Journal of Medicine, 2007
- Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon CancersCancer Research, 2005